Conference Coverage

Early PCI now favored in stable CAD


 

REPORTING FROM EUROPCR 2018

The long-term favorable impact of the early interventional strategy was striking: At 5 years, the rate of the primary composite endpoint of death, MI, or urgent revascularization was 13.9% in the early PCI group, roughly half of the 27% rate in the medically managed group. And this intention-to-treat analysis understates the true benefit of early PCI, since by the 5-year mark fully 51% of patients in the medically managed arm had crossed over to PCI.

The difference in the composite endpoint was driven largely by the early PCI group’s lesser need for urgent revascularization, defined as revascularization performed during any unplanned hospital admission for symptoms prompting revascularization. Most of these urgent revascularizations were prompted by in-hospital positive cardiac biomarkers, ECG changes, or unstable angina.

Dr. Panagiotis Xaplanteris of the Cardiovascular Center at Aalst, Belgium Bruce Jancin/MDedge News

Dr. Panagiotis Xaplanteris

Of note, patients who underwent early PCI had a long-term primary endpoint closely similar to that of a control group of patients who had stable angina with no hemodynamically significant stenoses.

An important finding that was not apparent during shorter-term follow-up is that, by the 5-year mark, the early PCI strategy conferred a significant reduction in the risk of acute MI: 8.1% versus 12%. This difference was mainly due to the early PCI group’s lower rate of nonprocedurally related spontaneous MI: 6.5% compared with 10.2% in the control group, for a 38% relative risk reduction.

Pages

Recommended Reading

Endovascular interventions associated with large benefits in peripheral artery disease
MDedge Cardiology
Interventionalists skeptical about public reporting of PCI
MDedge Cardiology
CABANA: AF ablation ties drug management, with an asterisk for crossovers
MDedge Cardiology
Device-related thrombus associated with ischemic events
MDedge Cardiology
Design limitations may have compromised DVT intervention trial
MDedge Cardiology
For in-stent restenosis, everolimus-eluting stents topped drug-eluting balloons
MDedge Cardiology
Sapien M3 mitral valve replacement data reported for first 10 patients
MDedge Cardiology
TAVR safe in low-risk aortic stenosis, early data indicate
MDedge Cardiology
FDA recalls HeartMate 3 LV assist device
MDedge Cardiology
Breakthrough in noninvasive assessment of multivessel CAD
MDedge Cardiology